Our successful attenuation of xenograft tumor growth, as well as tumor cell migratory and invasive capabilities with the integrin inhibitor SB273005, supports the importance of integrin binding for increased OS aggression correlated with ATRX loss. The gene discussed is ATRX; the disease is neoplasm.